Safety and efficacy of high-power short-duration radiofrequency ablation in patients with atrial fibrillation: a single-center randomized controlled trial

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400087516

Enrollment

Unknown

Registered

2024-07-29

Start date

2023-12-11

Completion date

Unknown

Last updated

2024-08-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atrial fibrillation

Interventions

High-power short-duration radiofrequency ablation :High power (70W, anterior wall 8-10s, posterior wall 5-6s) radiofrequency ablation of the pulmonary vein during surgery to restore sinus rhythm in pa

Conventional power ablation:Under the guidance of ablation index during surgery, traditional ablation power (40-45W, anterior wall 45W AI value 450-480, posterior wall 40W AI value 350-400) was used t

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Patients aged 18-80. 2.Patients with ECG or Holter-recorded atrial fibrillation (paroxysmal or less than 1 year of duration) who have not previously undergone catheter ablation for atrial fibrillation. 3.The patient is willing and able to comply with all requirements of the perioperative and follow-up protocols 4.The patient signed a written informed consent form for the research protocol 5.Patients can accept the follow-up required in the plan

Exclusion criteria

Exclusion criteria: 1. Patients with indications of pacemaker implantation. 2. Patients with systemic anticoagulation contraindications for heparin or coumarin or direct thrombin inhibitors. 3. Patients with left auricular thromboembolism. 4. Patients with LVEF<40%. 5. Patients with left atrium size =50mm (two-dimensional echocardiography, parasternal long-axis section). 6. Patients with severe mitral regurgitation. 7. Patients who are allergic to contrast media or iodine. 8. Patients with a history of cardiac surgery. 9. Patients with reversible AF etiology (such as hyperthyroidism or alcoholism). 10. Patients with life expectancy <12 months. 11. Patients in pregnancy. 12. Clear diagnosis of chronic obstructive pulmonary disease (COPD) patients. 13. In the assessment of the treating physician, the patient has a high probability of potential failure to adhere to the study requirements.

Design outcomes

Primary

Measure	Time frame
cerebral thromboembolism;	—

Secondary

Measure	Time frame
Rhythmic results;echocardiogram;Esophagoscopy examination;Assess athletic ability;No all-cause deaths within one year;	—

Countries

China

Contacts

Public ContactWei Li

Affiliated Hospital of Guizhou Medical University

Liwei249188@sina.com+86 138 0948 2491

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026